glp 1 and anti inflammatory Beyond Weight Loss: How GLP-1 Medicines Reduce Inflammation Across the Body Impact of GLP-1 on different

Choose the best setting for your wellness goals

Our Incredible Monthly Specials Are Strictly First In Best Dressed

Then the luciferase assays were carried out using the Dual-Glo Luciferase Assay System (Promega) with a BioTek synergy 4 Multi-Mode Microplate Reader

CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years

Nutrition counseling helps manage GLP-1 side effects by optimizing meal timing with 5-6 small meals daily, emphasizing hydration, balancing protein and fiber intake, and avoiding heavy, greasy, ultra-processed foods that can worsen digestive symptoms